Adaptation Or Attenuation Of Cells Patents (Class 435/245)
  • Publication number: 20080199926
    Abstract: The invention provides a non-naturally occurring microorganism having one or more gene disruptions, the one or more gene disruptions occurring in genes encoding an enzyme obligatory coupling 3-hydroxypropionic acid production to growth of the microorganism when the gene disruption reduces an activity of the enzyme, whereby the one or more gene disruptions confers stable growth-coupled production of 3-hydroxypropionic acid onto the non-naturally occurring microorganism.
    Type: Application
    Filed: January 22, 2008
    Publication date: August 21, 2008
    Inventors: Anthony P. Burgard, Stephen J. Van Dien
  • Publication number: 20080090283
    Abstract: Ethanol and furfural challenged strains of E. coli FBR5 exhibiting higher ethanol yield, productivity, and tolerance to both ethanol and furfural than FBR5 and methods for producing same.
    Type: Application
    Filed: October 12, 2007
    Publication date: April 17, 2008
    Applicant: Rowan Universtity
    Inventors: Brian Gerald Lefebvre, Mariano Javier Savelski, Gregory B. Hecht
  • Patent number: 7354593
    Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from three attenuated Eimeria species: E. acervulina, E. maxima and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: April 8, 2008
    Assignees: Merial Limited, University of Georgia Research Foundation, Inc.
    Inventors: Larry R. McDougald, Alberta Lorraine Fuller, Joyce Anita Pritchard
  • Publication number: 20080026999
    Abstract: The present invention relates to two-component lantibiotics isolated from Bacillus sp. Methods for producing said lantibiotics are provided, wherein dehydration and cyclization of the peptides is carried out by two substrate-specific modifying enzymes. Given the antimicrobial activity of the instant lantibiotics, methods for preventing or treating bacterial infections are also provided.
    Type: Application
    Filed: June 26, 2007
    Publication date: January 31, 2008
    Inventor: Wilfred A. van der Donk
  • Patent number: 7319028
    Abstract: The present invention provides a process for efficiently producing sporangia of Bacillus popilliae containing spores and parasporal bodies having controlling effects on Scarabaeidae insects, and a control agent and controlling method for Scarabaeidae insects obtained by said production process. In a process for producing sporangia of Bacillus popilliae containing spores and parasporal bodies by culturing Bacillus popilliae in a medium containing an adsorbent, the medium contains 0.2-4.0% by weight of glutamic acid.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: January 15, 2008
    Assignees: Dainippon Ink and Chemicals, Inc., Chiba Prefectural Government
    Inventors: Gaku Ehara, Masaharu Kimura, Hideji Nishihashi, Tomoko Yokoyama, Makoto Hasegawa, Masao Tanaka, Azusa Fujiie, Shinichi Aoyagi
  • Publication number: 20070281904
    Abstract: The present invention is directed to chitosan-derivative compounds and structures, methods of making chitosan-derivative compounds and methods for controlling, inhibiting and enhancing microbial populations in a variety of environments. The present invention is also directed to the control, inhibition and enhancement of microbial populations in animals, particularly humans. The microbial populations include bacteria, viruses and other pathogens where control of microbial populations are a necessity. The chitosan-derivative compounds of the present invention include chitosan-arginine compounds, related chitosan-L/D unnatural amino acid compounds, chitosan-acid amine compounds, chitosan-L/D natural amino acid derivative compounds, co-derivatives of the chitosan-derivative compounds, salts of the chitosan derivative compounds, and chitosan-guanidine compounds.
    Type: Application
    Filed: January 24, 2007
    Publication date: December 6, 2007
    Inventors: Shenda Baker, William P. Wiesmann, Shannon Ryan
  • Patent number: 7294491
    Abstract: The present invention provides a method for producing L-glutamic acid by fermentation, by culturing in a liquid medium a microorganism that can metabolize a carbon source at a specific pH, and wherein said medium contains a carbon source and L-glutamic acid at a saturation concentration, and wherein said microorganism is able to cause accumulation of an amount of L-glutamic acid in a liquid medium having said pH, wherein said amount exceeds the amount of L-glutamic acid at said saturation concentration when the pH of the medium is controlled so that L-glutamic acid is precipitated, making L-lysine exist in the medium when L-glutaminc acid concentration is lower than the concentration at which natural crystallization of L-glutamic acid occurs, and precipitating the ?-form crystals of L-glutamic acid.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: November 13, 2007
    Assignee: Ajinomoto Co., Inc.
    Inventors: Hiroshi Ueda, Kunihiko Toumori
  • Patent number: 7235246
    Abstract: The present invention relates to the preparation of universal inactivated vaccines and their use in preparing compositions for the prophylaxis and therapy of dermatomycosis. Vaccines according to the present invention have the advantage of conferring immunity against all important causes of dermatomycosis in animals and are characterized by stable immunogenic properties, easy preparation, high content of microconidia and lack of side reactions in animals.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: June 26, 2007
    Assignee: Boehringer Ingelheim Vetmedica, GmbH
    Inventors: Igor Polyakov, Ludmilla Ivanova
  • Patent number: 7192754
    Abstract: A material and a system are provided that efficiently inactivate a molting hormone by means of a protein having ecdysteroid 22-oxidase activity.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: March 20, 2007
    Assignee: National Institute of Agrobiological Sciences
    Inventors: Manabu Kamimura, Makoto Kiuchi, Hitoshi Saito, Maroko Myohara
  • Patent number: 7138126
    Abstract: A method for modifying a wild strain of an entero-invasive Shigella to produce a modified strain of Shigella that can be used for making a vaccine against the wild strain of Shigella. The genome of the wild strain of Shigella is transformed so that it cannot substantially invade cells of a human host and cannot spread substantially within infected cells and from infected to uninfected cells of the host and cannot produce toxins which will kill substantial numbers of the host's infected, as well as uninfected, cells. A first gene of the wild strain of Shigella, coding for a protein necessary for the Shigella to invade cells of the host, and a second gene, coding for a protein necessary for the Shigella to spread within infected cells and between the infected and uninfected cells of the host, are mutagenized.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: November 21, 2006
    Assignee: Institut Pasteur
    Inventors: Philippe Sansonetti, Annick Fontaine
  • Patent number: 7119167
    Abstract: The present invention relates to a 2227-bp DNA fragment that confers antiphage activity. Two proteins encoded by this DNA sequence are responsible for the phage resistance phenotype. When introduced in Lactococcus lactis phage-sensitive strain, this DNA fragment aborts infection of phages of the 936 and P335 species.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: October 10, 2006
    Assignee: Université Laval
    Inventors: Sylvain Moineau, Julie Bouchard, Éric Dion
  • Patent number: 7045336
    Abstract: We describe a bacterial delivery system for the delivery of DNA and antigens into cells. We constructed an attenuated bacterial vector which enters mammalian cells and ruptures delivering functional plasmid DNA and antigens into the cell cytoplasm. This Shigella vector was designed to deliver DNA to colonic surfaces, thus opening the possibility of oral and other mucosal DNA immunization and gene therapy strategies. The attenuated Shigella is also useful as a vaccine for reducing disease symptoms caused by Shigella.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: May 16, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Arthur A. Branstrom, Donata R. Sizemore, Jerald C. Sadoff
  • Patent number: 6998127
    Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from four attenuated Eimeria species: E. acervulina, E. maxima, E. mitis and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: February 14, 2006
    Assignee: Merial Limited
    Inventors: Larry R. McDougald, Alberta L. Fuller
  • Patent number: 6984388
    Abstract: A safe and effective live vaccine against Flavobacterium columnare of fish was created through the induction of an adhesion deficient isolate of Flavobacterium columnare using a ?-lactam antibiotic (ampicillin). Single immersion exposure of fish stimulated acquired immunity against virulent F. columnare infection.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: January 10, 2006
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Joel A. Bader, Craig A. Shoemaker, Phillip H. Klesius
  • Patent number: 6939705
    Abstract: A bacterial cell having protection against conditions which are lethal to an unprotected bacterial cell wherein, the protected cell is obtained by subjecting a bacterial cell to treatment with a sublethal level of stress.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: September 6, 2005
    Assignee: Nestec S.A.
    Inventors: Gudrun Schmidt, Ralf Zink
  • Patent number: 6916478
    Abstract: The invention relates to novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, methods for preparing same, and their use in the prevention and treatment of infectious diseases.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 12, 2005
    Assignee: University of Guelph
    Inventors: Jagath L. Kadurugamuwa, Terry J. Beveridge
  • Patent number: 6916646
    Abstract: Methods are provided for preparing improved fermentation strains of the family Enterobacteriaceae which comprise the steps of eliminating the cryptic plasmid from the progenitor strain thereby creating the improved strain. Methods for reducing the mobilization properties of resident plasmids in an Enterobacteriaceae strain containing a cryptic plasmid are also provided. The present invention provides the nucleic acid sequence of pS, a cryptic plasmid found in Pantoea which can be used to identify the cryptic plasmid in strains of Enterobacteriaceae.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: July 12, 2005
    Assignee: Genencor International, Inc.
    Inventors: Timothy Fowler, Stuart C. Causey
  • Patent number: 6908620
    Abstract: The present invention relates to a vaccine for coccidiosis in chickens prepared from four attenuated Eimeria species: E. acervulina, E. maxima, E. mitis and E. tenella. The vaccine was similar to or superior to other anticoccidial drugs in stimulating protective immunity against coccidiosis.
    Type: Grant
    Filed: December 8, 2003
    Date of Patent: June 21, 2005
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Larry R. McDougald, Alberta L. Fuller
  • Patent number: 6890542
    Abstract: The present invention relates to the use of a live mutant Leishmania in the preparation of a vaccine and to vaccine formulations for use in immunizing mammals, such as dogs and/or humans. The mutant Leishmania comprises at least one defective cysteine proteinase gene.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: May 10, 2005
    Assignee: University Court of the University of Glasgow
    Inventors: Jeremy Charles Mottram, Graham Herbert Coombs
  • Patent number: 6787360
    Abstract: The present invention provides a isolated bacteriophage useful as a tool for studying biological, biochemical, physiological and genetic properties of actinomycetes and other organisms which comprises a novel strain of Saccharomonospora having certain specified characteristics. The invention also relates to a process for the isolation of the said bacteriophage and/or DNA phage and to a novel universal growth medium which is particularly useful in the said process. Another embodiment of the process relates to a clonong vector which comprises a plasmid or bacteriophage comprising the phage DNA of the invention.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: September 7, 2004
    Assignee: Council of Scientific and Industrial Research
    Inventors: Pushpa Agrawal, Vishal Soni
  • Patent number: 6770275
    Abstract: The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.
    Type: Grant
    Filed: May 30, 1997
    Date of Patent: August 3, 2004
    Assignee: Akzo Nobel N.V.
    Inventors: Ruud Philip Antoon Maria Segers, Johannes Franciscus Van Den Bosch, Joachim Frey
  • Patent number: 6759230
    Abstract: A novel microorganism producing a nontoxic, non-antigenic exopolysaccharide is taught. The exopolysaccharide has neutral sugars migrating at the same rate as mannose, fucose, fructose and galactose, acidic sugars migrating at the same rate as fucose and amine sugars migrating at the same rate as glucose and fucose, and wherein the ratio of galactose:fucose:glucose:mannose is about 1:2:3:6. The microbe and the exopolysaccharide have uses as a biofilm in geologic applications and have several consumer uses as food and drug polymers and use as a plasma extender.
    Type: Grant
    Filed: October 25, 2000
    Date of Patent: July 6, 2004
    Assignee: The Board of Regents, The University of Texas
    Inventors: Lee A. Bulla, Jr., Mehmet Candas
  • Patent number: 6682914
    Abstract: Newly-isolated and purified metabolites which are effective in regulating the development of at least one filamentous fungal microorganism species are disclosed. These compounds, which are referred to as conidiogenol and conidiogenone, may be used to induce conidiation in and/or to inhibit the growth of populations of such fungal species. The compounds are preferably produced by culture of the fungal species Penicillium cyclopium, and may be subsequently recovered from the culture medium and purified. Methods of using and methods of producing these compounds are also disclosed.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: January 27, 2004
    Assignee: Universidad del Pais Vasco/Euskal Herriko Unibersitatea
    Inventors: Unai Ugalde, Tomas Roncal, Olov Sterner
  • Patent number: 6653135
    Abstract: An assay to determine the specific expression and suppression of proteins in response to a stressor is disclosed. An organism exposed to a stressor, including disease caused by exposure to, e.g., a parasite, or a substance suspected of causing an adverse effect, is assayed to determine a first set of proteins expressed and a second set of proteins suppressed in response to the stressor. The amount of each protein expressed and the amount of each protein suppressed can be statistically analyzed to determine which proteins are most useful in diagnosing the stressor. A protein profile for a first stressor can be compared to protein profiles for a second stressor, a third stressor, etc. A distinct protein expression signature (PES) for the first stressor can be identified by determining subsets fo proteins expressed and/or suppressed only in response to the first stressor.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: November 25, 2003
    Assignee: University of Maryland
    Inventor: Brian P. Bradley
  • Patent number: 6593087
    Abstract: This invention describes novel purified and isolated nucleic acid molecules or the fragments thereof, extracted from nematode or arthropod pests or recombinant, which encode P-glycoprotein homologs and regulate resistance to the macrocyclic lactone compounds. The invention further relates to the new P-glycoprotein homolog expression product of these nucleic acids. Also described herein are methods for detecting the gene encoding for resistance to the macrocyclic lactone compounds in nematode or arthropod pests which comprise comparing the nucleic acids extracted from a pest specimen to the nucleic acids encoding for resistance and the nucleic acids encoding for susceptibility to the macrocyclic lactone compounds.
    Type: Grant
    Filed: December 27, 2000
    Date of Patent: July 15, 2003
    Assignee: McGill University
    Inventors: Roger K. Prichard, Ming Xu, Ana Paula Ribeiro, William J. Blackhall, Robin N. Beech, Marcelo Molento, Hao Yuan Liu
  • Patent number: 6589771
    Abstract: A method for arousing dormant bacteria. The method comprises inducing diffusion of intracellular solutes from dormant bacteria and then allowing an adjustment period for a length of time sufficient to initiate arousal. The decrease in intracellular osmolality or pH can be induced by methods such as extraction, dilution, or dialysis. The method has been standardized using Dulbecco's phosphate buffered saline as the solution. The aroused bacteria can then be selected or recovered by growing them on media for a period of time. If the adjustment period is prolonged, many bacteria can become hypermutative.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: July 8, 2003
    Assignee: Immunom Technologies, Inc.
    Inventor: William E. Marshall
  • Patent number: 6534054
    Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: March 18, 2003
    Assignee: The Bio Balance Corporation
    Inventors: Mark Olshenitsky, Genadi Buchman
  • Patent number: 6514494
    Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: February 4, 2003
    Assignee: The Bio Balance Corporation
    Inventors: Mark Olshenitsky, Genadi Buchman
  • Publication number: 20020173031
    Abstract: The present invention relates to methods for modulating the resistance of cells to foreign compounds, i.e. drugs, antibiotics, etc by altering the ATP gradient across biological membranes. The altering of the ATP gradient across biological membranes is achieved through the manipulation of ecto-phosphatase activity and ABC transporter molecule activity which may be useful to confer herbicide resistance to plants, confer antibiotic resistance to bacteria, confer drug resistance to yeast cells, or to reduce resistance in cells to facilitate chemotherapeutic treatments, and to reduce resistance in bacteria and yeast. The present invention is also directed to the methods for identifying ecto-phosphatase inhibitors and uses thereof.
    Type: Application
    Filed: January 14, 2002
    Publication date: November 21, 2002
    Applicant: The University of Texas System
    Inventors: Collin E. Thomas, J. Brian Windsor, Stan J. Roux, Alan M. Lloyd, Laurence Hurley
  • Publication number: 20020127701
    Abstract: A method of disrupting biological material includes drying particulate material, mixing the material with a gas under pressure, releasing the pressure explosively and collecting the resultant product. The biological starting material is any particulate material and includes: cells with membranes, cells with rigid cell walls, non-cellular biological material, intra-cellular material, and unbounded homogenous material. Apparatus for batch, semi-continuous and continuous operation of the method is provided. Included is a chamber with at least one inlet valve and at least one outlet valve and collection means. The chamber is capable of withstanding at least 800 bar, preferably 30 bar pressure. The particle size of the starting material is in the range 0.1 to 2000 &mgr;m and of the resultant product, less than 2 &mgr;m.
    Type: Application
    Filed: November 30, 1999
    Publication date: September 12, 2002
    Inventor: KELVIN WINSTON DUNCAN
  • Patent number: 6410265
    Abstract: This invention relates to the isolation of a novel putative efflux gene from Pseudomonas mendocina. The putative efflux gene is useful for probing an organism's efflux system to gain an understanding of the mechanisms of solvent tolerance. The invention further provides a Pseudomonas mendocina strain deficient in this gene. This strain is unable to grow in the presence of chloramphenicol and, compared to the wildtype strain, grows slowly in the presence of high concentrations of PHBA.
    Type: Grant
    Filed: October 30, 1998
    Date of Patent: June 25, 2002
    Assignee: E. I. du Pont de Nemours and Company
    Inventor: Kevin Keqin Chen
  • Patent number: 6410021
    Abstract: A live vaccine of recombinant mutants of a member of the family Pasteurellaceae lacking a rib gene necessary for production of riboflavin as well as a method of vaccination therewith is described. The vaccine is effective against members of the family Pasteurellaceae.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: June 25, 2002
    Inventors: Troy E. Fuller, Martha H. Mulks, Bradley Thacker
  • Patent number: 6410012
    Abstract: This invention pertains in part to a method for delivering functional DNA or antigens. The desired DNA is introduced into attenuated bacteria able to enter cells. Once the bacteria is in the cell, antimicrobial agents are introduced such that they enter the mammalian cell and lyse the bacteria thereby allowing the delivery of carried functional DNA or antigens. The advantages of this method and its uses are described.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: June 25, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Donata R. Sizemore, Jerald C. Sadoff, Jason C. Grove
  • Patent number: 6376228
    Abstract: A method for vaccinating poultry to prevent salmonellosis and other microbial-related health problems in humans is described. The method involves isolation of a poultry heterophil-adapted strain of a microorganism that may be used in a vaccine. A vaccine comprising a preparation of the poultry heterophil-adapted strain is administered to poultry to reduce the transmission of microorganisms causing salmonellosis and other illnesses.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: April 23, 2002
    Assignee: Iowa State University Research Foundation, Inc.
    Inventor: Theodore T. Kramer
  • Patent number: 6376245
    Abstract: The invention provides a process for protecting whole eukaryotes or parts thereof from an invasive attack from an invasive agent which comprises, selecting a prokaryotic bacterium which is capable of forming an L-form association with a host eukaryote and introducing an L-form bacteria into said host, wherein the bacteria is also selected to be antagonistic to the invasive agent. This process allows the protection of plants and plant parts against invasive organisms with which they have not already had contact.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: April 23, 2002
    Assignee: Aberdeen University
    Inventor: Alan McEwan Paton
  • Publication number: 20020045587
    Abstract: The invention relates to the introduction of DNA or RNA sequences into a mammalian cell to achieve controlled expression of a polypeptide. It is therefore useful in gene therapy, vaccination, and any therapeutic situation in which a polypeptide should be administered to a host or cells of said host, as well as for the production of polypeptides by mammalian cells, e.g., in Culture or in transgenic animals.
    Type: Application
    Filed: March 22, 2000
    Publication date: April 18, 2002
    Inventor: Werner Goebel
  • Patent number: 6350608
    Abstract: A process is provided for the biological digestion of animal carcasses. First, the carcass is cut into smaller pieces with equipment that masticates, grinds or comminutes in the presence of water to create a solid-liquid mixture. The next steps include treating the solid-liquid mixture with a special blend or combination of bacteria that have been specifically cultured to digest the carcass; the mixture is subsequently aerated to form a stabilized biomass. The stabilized biomass is aerated in an open basin to further digest and liquefy the carcass, water, bacteria mixture. From the open basin, the primarily liquid waste stream is passed to a clarifying tank where the suspended solids are precipitated as sludge, thus clarifying the liquid. Sludge is removed from the clarifying chamber and the clarified liquid is either discharged or recirculated for further use in this novel process.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: February 26, 2002
    Assignee: AJT & Associates, Inc.
    Inventors: Alfredo J. Teran, Richard G. Wood, W. Todd Willoughby
  • Patent number: 6323025
    Abstract: Compounds termed “vitaletheine modulators” which include beta-alanyl-taurine and carbobenzoxy beta-alanyl-taurine are synthesized and added to culture media for in vitro culture of cells such as mammalian or plant cells. The compounds support cell vitality, and provide increased cellular life span, increased cellular bioproductivity, improved cellular function, and adaption of resistant cells to culturing. The compounds further delay senescence, optimize growth and maturation, and increase population doublings.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 27, 2001
    Assignee: University of New Mexico
    Inventors: Galen D. Knight, Terence J. Scallen
  • Patent number: 6312955
    Abstract: The present invention features gram-positive bacteria resistant to 5-fluorodeoxyuridine (FUdR). Such bacteria will preferably be commensal, and will not be resistant to antibiotics. Bacteria according to the present invention may also be transformed with DNA encoding an antigenic protein. Such transformed bacteria may be used to formulate a vaccine, in order to stimulate an immune response to the antigenic protein in a patient. The present invention further provides a method for isolating gram-positive bacteria resistant to FUdR.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: November 6, 2001
    Assignee: Siga Pharmaceuticals
    Inventors: Dennis E. Hruby, Christine A. Franke
  • Patent number: 6309650
    Abstract: An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: October 30, 2001
    Assignees: Cheil Jedang Corporation, The United States of America as represented by the Secretary of the Army
    Inventors: Hyun Su Kim, Wang Don Yoo, Soo Ok Kim, Sung Hee Lee, Sang Bum Moon, Sun Pyo Hong, Yong Cheol Shin, Yong Ju Chung, Kenneth H. Eckels, Bruce Innis, Joseph R. Puniak, Leonard N. Binn, Ashok K. Srivastava, Doria R. Dubois
  • Patent number: 6294351
    Abstract: A method of biochemically transforming macromolecular compounds found in solid carbonaceous materials, such as coal is provided. The preparation of new microorganisms, metabolically weaned through challenge growth processes to biochemically transform solid carbonaceous materials at extreme temperatures, pressures, pH, salt and toxic metal concentrations is also disclosed.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: September 25, 2001
    Assignee: Brookhaven Science Associates, LLC
    Inventors: Mow S. Lin, Eugene T. Premuzic
  • Patent number: 6287873
    Abstract: A microbial consortium, ATCC 202177, is enriched to remove target sulfur compounds from gases in the presence of ammonia, cyanide, carbon monoxide, and other toxic gases and mixtures thereof. The ATCC 202177 consortium is cultured in an anaerobic or aerobic nutrient medium until enough cells of ATCC 202177 are recovered to remove the target sulfur species at a pressure ranging from 1 to 80 atmospheres.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: September 11, 2001
    Assignee: Arctech Inc.
    Inventors: Kailish C. Srivastava, Seema Garg, Daman S. Walia
  • Publication number: 20010018204
    Abstract: Compositions and methods for inhibiting cellular proliferation wherein the composition contains Tissue Factor Pathway Inhibitor (TFPI), a TFPI homolog, or an active fragment thereof. TFPI exhibits potent anti-proliferative activity on human and other animal cells, particularly endothelial cells. More particularly, the TFPI, TFPI homolog, and inhibitory fragment thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.
    Type: Application
    Filed: January 22, 2001
    Publication date: August 30, 2001
    Inventors: Adonia E. Papathanassiu, Shawn J. Green
  • Patent number: 6235517
    Abstract: This invention relates to the isolation of thermophilic phytase-producing microorganisms, method for producing phytase using such microorganisms, phytase obtained therefrom, and usage of the phytase to hydrolyze phytic acid or phytate. In particular, this invention relates to phytase-producing microorganisms, which belong to Streptomyces sp., Pseudonocardia sp. or Microbispora sp., and which produce phytase available for recovery in an efficient and practical manner.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: May 22, 2001
    Assignee: Food Industry Research & Development Institute
    Inventors: Jaw-Shiow Chu, Su-Fang Chung, Min Tseng, Chiou-Yen Wen, Wen-Shen Chu
  • Patent number: 6204003
    Abstract: The claimed invention is a method for determining whether a mammal is infected with Haemobartonella felis or for inducing an immune response against Haemobartonella felis using a polypeptide expressed by Mycoplasma. Preferably, the polypeptide is expressed by Mycoplasma gallisepticum. In a preferred embodiment the polypeptide is the pMGA protein expressed by the strain of Mycoplasma gallisepticum having ATCC deposit number 19610.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: March 20, 2001
    Assignee: Synbiotics Corporation
    Inventors: J. Kevin Steele, David L. Telford, John A. Cutting
  • Patent number: 6180390
    Abstract: This invention relates to the isolation of thermophilic phytase-producing microorganisms, method for producing phytase using such microorganisms, phytase obtained therefrom, and usage of the phytase to hydrolyze phytic acid or phytate. In particular, this invention relates to phytase-producing microorganisms, which belong to Streptomyces sp., Pseudonocardia sp. or Microbispora sp., and which produce phytase available for recovery in an efficient and practical manner.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: January 30, 2001
    Assignee: Food Industry Research & Development Institute
    Inventors: Jaw-Shiow Chu, Su-Fang Chung, Min Tseng, Chiou-Yen Wen, Wen-Shen Chu
  • Patent number: 6136554
    Abstract: The present invention is directed to methods and media for the growth, enrichment, isolation, and presumptive identification of enteric pathogens such as E. coli 0157:H7 and Salmonella. In particular, the organisms commonly associated with gastrointestinal infections of humans and other animals are distinguished based on their growth, colonial morphology and color. The present invention is also directed to methods and media for the growth, enrichment, isolation and presumptive identification of enteric pathogens such as E. coli 0157:H7 and Salmonella isolated from food, water, dairy, and environmental samples.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: October 24, 2000
    Assignee: Biolog, Inc.
    Inventor: Barry Bochner
  • Patent number: 6132709
    Abstract: A method for treating cattle and sheep to prevent foot rot and/or liver necrosis comprising administering a Fusobacterium necrophorum bacterin which is a .beta.-propriolactone inactivated Fusobacterium necrophorum isolate to the animal being treated.
    Type: Grant
    Filed: January 24, 1992
    Date of Patent: October 17, 2000
    Assignee: Bayer Corporation
    Inventor: John N. Berg
  • Patent number: 6120774
    Abstract: A method for vaccinating poultry to prevent salmonellosis and other microbial-related health problems in humans is described. The method involves isolation of a poultry heterophil-adapted strain of a microorganism that may be used in a vaccine. A vaccine comprising a preparation of the poultry heterophil-adapted strain is administered to poultry to reduce the transmission of microorganisms causing salmonellosis and other illnesses.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: September 19, 2000
    Assignee: Iowa State University Research Foundation, Inc.
    Inventor: Theodore T. Kramer
  • Patent number: RE39494
    Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: February 27, 2007
    Assignee: Intervet Inc.
    Inventors: Gerald R. Fitzgerald, C. Joseph Welter